Title: POLYSACCHARIDE DERIVATIVES OF LIPOIC ACID, THEIR PREPARATION, USE AS SKIN COSMETICS AND MEDICAL DEVICES

Abstract: Disclosed are polysaccharides containing residues of glucosamine or galactosamine in the repetitive unit, characterised by the presence of esters on the hydroxyls or amides on the amine functions, with lipoic acid or with mixtures of lipoic acid and formic acid.
Summary of the invention

The present invention discloses novel polysaccharide derivatives containing glucosamine or galactosamine residues in the repetitive unit, characterised by the presence of esters on the hydroxyls or amides on the amine functions, with lipoic acid or with mixtures of lipoic acid and formic acid, their preparation by an original synthesis method wherein the formate ester, if any, originates from formamide, and their purification and use as skin protection substances.

State of the art

Lipoic acid (or thioctic acid) is a natural molecule, isolated in mammal livers, which acts as an essential cofactor for many enzymatic reactions, including the conversion of pyruvate to Acetyl-CoA in the Krebs cycle. Lipoic acid is a potent antioxidant which prevents the symptoms of vitamin C and vitamin E deficiency, and also a powerful scavenger of reactive species, namely free radicals such as hydroperoxides, superoxides, peroxynitrites, etc.

Esters of some polysaccharides are known, such as cellulose with lipoic acid; lipoic acid esters with synthetic polymers (PEG); lipoic acid esters or amides with small molecules, and formulations based on physical mixtures of lipoic acid or derivatives thereof with hyaluronic acid (HA) (and derivatives thereof) or with chondroitin sulphate (CS).

Materials based on microcrystalline cellulose derivatised with lipoic acid by esterification under homogenous conditions in dimethylacetamide (DMAc)/LiCl with carbonyldiimidazole (CDI) at the temperature of 60°C have been described (Polymer Bulletin, 57, 2006, pp 857-863). The products
obtained tend to chelate gold atoms, and are therefore suitable to coat gold leaf to produce supports for biomineralisation, crystal growth and immobilisation of enzymes. Cellulose esters with lipoic acid are reported which have a maximum degree of substitution (DS) of 1.45, and are insoluble in common solvents from DS 0.50.

Dextran and beta-cyclodextrin derivatised with lipoic acid by esterification under homogenous conditions in DMSO with CDI at the temperature of 80°C (one-pot reaction) have been described (Polymer Bulletin, 59, 2007, pp 65-71). Dextran esters with lipoic acid which have a maximum DS of 0.44, and beta-cyclodextrin esters with lipoic acid which have a maximum DS of 1.99, both insoluble in common solvents, have been reported. Said materials are designed to produce surface coatings for systems able to interact with biological or organic molecules.

Microcrystalline cellulose derivatised with lipoic acid by esterification under homogenous conditions in DMAc/LiCl with dicyclohexyl-carbodiimide (DCC) and dimethylamino-pyridine (DMAP) at the temperature of 40°C has been described (Macromolecular Bioscience, 7, 2007, DOI:10.1002/mabi.200700110). The products obtained demonstrate antioxidant activity of potential use in the manufacture of blood-compatible membranes for use in the haemodialysis process (chemical and biomedical industry), and have a maximum DS of 0.58. Said polymer products show an increase in metabolic stability and a decline in the breakdown rate of the antioxidant molecule bonded to them. Said polymers are required to have a molecular weight sufficiently high to ensure that they do not cross the blood-brain barrier and damage the cell membranes.

WO 2007/105854 discloses the synthesis of water-soluble esters of lipoic acid with polyethylene glycol (PEG with various molecular weights) for use in external topical applications as an antioxidant, bleaching agent and
anti-aging product; it describes a process of derivatisation of lipoic acid by EDCI (l-ethyl-S-^'-dimethyaminopropylcarboimide) and DMAP.

WO 02/076935 describes novel derivatives of lipoic acid obtained by means of an amide bond of lipoic acid to aminoacids. Said products show biological activity.

US 6,365,623 discloses a topical formulation for the treatment of acne based on lipoic acid and ester and amide derivatives thereof. HA is mentioned as a further additive in the formulation.

WO 2006/128618 discloses novel formulations based on lipoic acid and HA or derivatives thereof for use in the pharmaceutical and cosmetic fields, due to their effect of regenerating damaged skin, preventing skin aging and repairing chronic ulcers. Said formulations can be administered topically or systemically (orally, by injection, etc.).

WO 2005/041999 describes novel formulations for diet supplements designed to improve the joint functions, reduce inflammation and repair cartilage. The various possible components mentioned include chondroitin sulphate and lipoic acid.

However, no examples of lipoic acid covalently bonded via an ester or amide bond to glycosaminoglycans or chitosan are reported in the literature.

**Description of the invention**

The present invention discloses novel polysaccharide derivatives containing residues of glucosamine or galactosamine in the repetitive unit partly esterified or amidated with lipoic acid, or with lipoic acid and formic acid simultaneously.

The degree of substitution (DS) of lipoic esters on the hydroxyls of each polysaccharide monomer ranges between 0.01 and 0.5*N in the case of esters and between 0.01 and 1 for amides, where N is the number of free alcohol groups present in the repetitive unit, while the degree of esterification of
formic acid on the polymer hydroxyl groups, when it is present, is between 0.01 and 0.2 (i.e. between 1% and 20%). The polysaccharides derivatised according to the invention are glycosaminoglycans (hyaluronic acid, chondroitin sulphate, dermatan sulphate, heparan sulphate and cheratan sulphate) and chitosan; in this latter case, the bond between polymer and lipoic acid is an amide bond, and involves the amine group at the 2-position of the glucosamine residue.

The carboxyl function of the polysaccharide derivatives may be salified with alkaline metals, in particular sodium.

The molecular weight of the polysaccharide falls into the interval between $10^3$ and $10^7$ daltons, and between $10^4$ and $10^6$ daltons in the case of the hyaluronic acid derivative. The latter will preferably have a degree of esterification of lipoic acid at the hydroxyl groups of the polymer ranging between 0.01 and 0.8, while the degree of esterification of formic acid at the hydroxyl groups of the polymer is between 0 and 0.20, and the degree of crosslinking is between 0.001 and 0.1, as regards the ester groups between two different hyaluronic acid chains.

The degree of esterification or amidation can be modulated according to the characteristics of the starting polysaccharide and the reaction conditions used, such as the stoichiometric ratios between polysaccharide substrate and activated lipoic acid, the type and quantity of catalytic base used, and the reaction temperature. For example, in the case of hyaluronic acid lipoic derivatives, by changing the synthesis conditions it is possible to obtain soluble straight-chain polymers or cross-linked hydrogels containing, in addition to lipoic esters, esters between the hydroxyl groups of one chain and the carboxyl groups of the glucuronic acid unit belonging to a different chain. This latter bond constitutes the crosslinking bridge. The hydrogels acquire significant viscoelastic properties, which have been studied from the
rheological standpoint and are described below.

The straight-chain (non-crosslinked) derivatives according to the invention can be used in topical compositions with a moisturising, elasticising, toning, anti-aging or anti-acne action or as adjuvants for the treatment of skin lesions such as inflammations, ulcers, wounds, dermatitis, and skin hyperthermia caused by radiation. The polysaccharide concentration may be between 0.05% and 5% by weight of the composition. Examples of suitable formulations include creams, ointments, gels, hydrophilic liquids, aqueous or water-alcohol lotions, oil/water or water/oil emulsions.

The crosslinked derivatives, in hydrogel form, can be introduced into sterile syringes and used as medical devices for intra-articular use as viscosupplementation agents and skin fillers in cosmetic surgery. The medical devices according to the invention will contain a hydrogel of hyaluronic acid lipoate swollen in sterile saline solution, at a polymer concentration of between 0.5% and 3% weight/volume.

A medical device containing a hyaluronic acid derivatised according to the invention, with a molecular weight ranging between $10^4$ and $10^6$ daltons, can also be advantageously used as eyedrops for the treatment of forms of conjunctivitis and keratitis with different etiologies.

The invention also relates to the process for the preparation thereof, which comprises:

a. Dissolution of the selected polysaccharide in the form of an alkaline metal (generally sodium) salt, or in chlorinated form in the case of chitosan, in an organic solvent, in particular formamide (FA);

b. Activation of lipoic acid through carbonyldiimidazole solubilised in an organic solvent such as dimethylacetamide (DMA), FA, DMF, DMSO, etc., in particular DMA, thereby obtaining
lipoyl-imidazolide;

c. Addition to the polymer solution of a basic catalyst, preferably dimethylaminopyridine (DMAP) or triethylamine, and of the solution containing lipoyl-imidazolide, in the chosen quantities; in the synthesis of autocrosslinked hyaluronic acid lipoate the basic catalyst is avoided, and an excess of carbonyldiimidazole is used.

d. Reaction at a controlled temperature (usually room temperature) for defined times, followed by dilution of the reaction mixture with a solution buffered to physiological pH;

e. Purification of the end products by precipitation, dialysis or tangential filtration;

f. Recovery of the product by filtration, freeze-drying or spray-drying.

The base is an aromatic or aliphatic organic base comprising one atom of trisubstituted nitrogen, preferably dimethylaminopyridine, 4-pyrrolidine-pyridine or triethylamine. The solubilisation temperature of the polysaccharide in formamide is typically between 60°C and 120°C, and preferably 95°C.

In the case of crosslinked hyaluronic acid, the process comprises the following steps:

a) dissolving hyaluronic acid salified with sodium or other alkaline metals in formamide, by heating;

b) adding to the resulting solution, lipoic acid pre-activated with carbonyldiimidazole, at room temperature;

c) reacting the reaction mixture at room temperature for between 4 and 24 hours;

d) diluting the reaction mixture with a buffered aqueous solution and neutralising it to pH 6-7.5;
e) purifying the dilute reaction mixture by dialysis;
f) freezing the purified aqueous polysaccharide solution and recovering the product by freeze-drying.

Formate ester, when present, originates in the process according to the invention by hydrolysis of formamide under the experimental conditions used.

The following examples describe in detail the synthesis of some polysaccharide derivatives of lipoic acid according to this invention.

**Examples**

The $^1$H NMR tests are carried out in D$_2$O or DMSO-d6 with a Bruker Avance 400 spectrometer equipped with a 5 mm multinuclear probe with a z gradient, at 300$^0$K. The tests include Diffusion Ordered Spectroscopy (DOSY); these latter experiments demonstrate the existence of a covalent bond between the polymer and lipoic acid. Quantitation of the esterified lipoic acid residues (degree of substitution, DS) is performed after exhaustive hydrolysis with NaOD directly in the NMR tube. The $^1$H spectrum of the hydrolysate allows the signals attributable to lipoic acid and those attributable to the polysaccharide to be integrated; their ratio provides the DS. Similarly, the DS is evaluated in formate esters, when present.

**Example 1. Synthesis of hyaluronic acid lipoic ester**

1.50 grams of HA sodium salt is solubilised in 30 ml of formamide (5.0% w/v) at 95$^0$C for 2 hours; the temperature is then reduced to 25$^0$C, and 911 mg of DMAP is added to the solution. 770 mg of lipoic acid is solubilised separately in 2.0 ml of DMA, and reacted with 604 mg of CDI for 30 min. at 25$^0$C. The resulting solution containing the lipoylimidazolide is dropped into the solution of HA, DMAP and formamide, and the reaction proceeds under mechanical stirring for 20 hours at 25$^0$C. 300 ml of water containing a phosphate buffer ($\text{KH}_2\text{PO}_4/\text{K}_2\text{HPO}_4$), 0.25M at pH 6, is then added, and purification by dialysis is performed. The aqueous solution is then frozen and
freeze-dried. 1.48 g of lyophilisate is recovered.

10 mg of sample is solubilised in 0.7 ml of D₂O and transferred to an NMR tube.

Figure 1 shows the ¹H NMR spectra of hyaluronic acid lipoic ester before (bottom) and after (top) hydrolysis of the esters by adding NaOD.

The bottom spectrum is obtained by applying a DOSY sequence which only retains the signals attributable to chemical groups covalently bonded to the polymer.

A DS value of 0.50 is obtained from integration of the methylene signals associated with lipoic acid (Fig. 1); the DS in formate amounts to 0.02.

**Example 2. Synthesis of hyaluronic acid lipoic ester without the use of a catalyst**

125 mg of HA sodium salt is solubilised in 5 ml of formamide (2.5% w/v) at 95°C for 2 hours; the temperature is then reduced to 25°C.

192 mg of lipoic acid is solubilised separately in 1 ml of DMA, and reacted with 151 mg of CDI for 30 min. at 25°C. The resulting solution containing the lipoylimidazolide is dropped into the HA and formamide solution, and the reaction proceeds under stirring for 20 hours at 25°C. The sample is recovered by precipitation in acetone. After two washes in acetone and drying under vacuum, 112 mg of sample is recovered.

10 mg of sample is solubilised in 0.7 ml of DMSO-d₆ acidified with TFA while hot, and transferred to the NMR tube. A DS value of 0.25 is obtained from integration of the methylene signals associated with lipoic acid.

**Example 3. Synthesis of hyaluronic acid lipoic ester purified by ultrafiltration**

250 mg of HA sodium salt is solubilised in 5 ml of formamide (5.0% w/v) at 95°C for 2 hours; the temperature is then reduced to 25°C, and 152 mg of DMAP is added to the solution. 128 mg of lipoic acid is solubilised
separately in 0.6 ml of DMA, and reacted with 101 mg of CDI for 30 min. at 25°C. The resulting solution containing the lipoylimidazolide is dropped into the HA, DMAP and formamide solution, and the reaction proceeds under stirring for 20 hours at 25°C. The sample is recovered by ultrafiltration. 225 mg of sample is frozen and recovered by freeze-drying.

10 mg of sample is solubilised in 0.7 ml of D₂O and transferred to an NMR tube. A DS value of 0.47 is obtained from integration of the methylene signals associated with lipoic acid; the DS in the formate residues amounts to 0.04.

**Example 4. Synthesis of straight-chain hyaluronic acid lipoic ester with a high degree of substitution**

250 mg of HA sodium salt is solubilised in 5 ml of formamide (5.0% w/v) at 95°C for 2 hours; the temperature is then reduced to 25°C, and 228 mg of DMAP is added to the solution. 385 mg of lipoic acid is solubilised separately in 1.5 ml of DMA, and reacted with 302 mg of CDI for 30 min. at 25°C. The resulting solution containing the lipoylimidazolide is dropped into the HA, DMAP and formamide solution, and the reaction proceeds under stirring for 20 hours at 25°C. The sample is recovered by precipitation in acetone. After two washes in acetone and drying under vacuum, 220 mg of sample is recovered.

10 mg of sample is solubilised in 0.7 ml of DMSO-d₆ acidified while hot with TFA, and transferred to an NMR tube. A DS value of 1.8 is obtained from integration of the methylene signals associated with lipoic acid; the DS in the formate residues amounts to 0.07.

**Example 5. Synthesis of crosslinked hyaluronic acid lipoic ester**

500 mg of HA sodium salt is solubilised in 10 ml of formamide (5.0% w/v) at 95°C for 2 hours; the temperature is then reduced to 25°C. 180 mg of lipoic acid is solubilised separately in 1 ml of DMA, and reacted
with 202 mg of CDI for 30 min. at 25°C. The resulting solution containing the
lipoylimidazolide is dropped into the HA solution in formamide, and the
reaction proceeds under mechanical stirring for 20 hours at 25°C. 30 ml of
water is then added, the pH is adjusted to 6.5 with solid KH₂PO₄, and
purification by dialysis is performed. The aqueous solution is then frozen and
freeze-dried. 490 mg of crosslinked lyophilisate is recovered, as demonstrated
by the rheological studies illustrated in figures 2 and 3.

10 mg of sample is solubilised in 0.7 ml of D₂O, pH 11, and transferred
to an NMR tube. A DS value of 0.10 is obtained from integration of the
methylenes signals associated with lipoic acid; the DS in the formate residues
amounts to 0.02.

Example 6. Synthesis of chondroitin sulphate lipoic ester

1.0 grams of CS sodium salt is solubilised in 5 ml of formamide
(20% w/v) at 80°C for 20 minutes; the temperature is then reduced to 25°C,
and 488 mg of DMAP is added to the solution. 412 mg of lipoic acid is
solubilised separately in 1.0 ml of DMA, and reacted with 324 mg of CDI for
30 min. at 25°C. The resulting solution containing the lipoylimidazolide is
dropped into the CS, DMAP and formamide solution, and the reaction
proceeds under mechanical stirring for 20 hours at 25°C. 20 ml of water is
then added, the pH is adjusted to 7 with solid 0.5M HCl, and purification by
ultrafiltration is performed. The aqueous solution is then frozen and
freeze-dried. 850 mg of lyophilisate is recovered.

10 mg of sample is solubilised in 0.7 ml of D₂O and transferred to an
NMR tube. A DS value of 0.70 is obtained from integration of the methylene
signals associated with lipoic acid; the DS in the formate residues amounts to
0.02.

Example 7. Synthesis of lipoic chitosan amide

200 mg of freeze-dried chitosan hydrochloride (obtained by solubilising
chitosan flakes in water acidified with hydrochloric acid at pH 3, and then freeze-drying the solution) was solubilised in 4 ml of formamide (5.0% w/v) at 95°C for 10 min. 104 mg of lipoic acid was solubilised separately in 0.5 ml of DMA, and reacted with 82 mg of CDI for 30 min. at 25°C. The resulting solution containing the lipoylimidazolide is dropped into the chitosan and formamide solution, and the reaction proceeds under mechanical stirring for 20 hours at 25°C. 20 ml of water is then added, the pH is adjusted to 7 with 0.5M HCl, and purification is performed by dialysis. The aqueous solution is then frozen and freeze-dried. 171 mg of lyophilisate is recovered.

10 mg of sample is solubilised in 0.7 ml of D₂O acidified with trifluoroacetic acid and transferred to an NMR tube. A DS value of 0.23 is obtained from integration of the methylene signals associated with lipoic acid; the DS in the formate residues amounts to 0.03.

**Example 8. Preparation of an O/W elasticising cream**

A non-limiting example of the invention, which illustrates the preparation of a cream formulation containing one of the lipoic acid esters according to the invention, is set out below.

The O/W cream formulation contains the compound described in example 1 as functional agent, at the concentration of 0.1%, suitably mixed with common excipients used in skin cosmetics, such as emulsifiers, thickeners, oils, moisturisers, gelling agents, preservatives, etc..

Briefly, the process is as follows:

Approximately 600 ml of demineralised water (corresponding to approx. 60% by weight of the total formulation) is loaded into a turboemulsifier, and the pre-melted fatty phase is added under stirring at approx. 70°C. The mixture is emulsified, and cooled slowly to the temperature of 35-40°C. The thermolabile and volatile constituents are added at this temperature, followed by the HA sodium salt lipoic ester described in example
1, dissolved in a suitable quantity of water. The mixture is left under slow stirring until the temperature of 25-30°C is reached, and the finished product is then discharged into a suitable container.

The result is a cream with the following composition (% W/W):  

- Sodium HA lipoic ester (Example 1) 0.1  
- Oils (palmitic/caprylic glycerides-triglycerides) 12  
- Non-ionic emulsifiers 6  
- Cetyl alcohol 2  
- Dimethicone 4  
- MgAl silicate 2  
- Glycerin 3  
- Xylitol 2  
- Parabens 0.7  
- H₂O q.s. to 100

**Example 9. Preparation of a medical device in the form of a syringe containing 1.5 ml of a hydrogel containing 2% w/w of crosslinked HA lipoate obtained as described in example 5**

30 mg of autocrosslinked esterified polymer in lyophilisate form, obtained as described in example 5, is weighed in a sterile 2.0 ml syringe; the syringe is filled with 1.47 g of an aqueous solution of 0.9% NaCl (w/V). All the experimental procedures are conducted under a laminar-flow hood using endotoxin-free materials; the above-mentioned saline solution is also prepared with water for injectable use. The polymer is left to swell for 24 hours at room temperature. The syringe is then steam-sterilised in accordance with a standard cycle at 121°C for 16 minutes in the autoclave.

**Rheological study of hyaluronic acid esterified with lipoic acid and autocrosslinked**

A comparative rheological study was conducted on two samples of
hyaluronic acid lipoic ester obtained under different experimental conditions: the first, described in example 1, was solubilised in water to provide a viscous solution, while the second, described in example 5, provided a microgel dispersion. A commercial hyaluronic acid solution with a molecular weight of Mw = 300kDa, employed for the two syntheses, was used as reference. All three systems contained the same weight concentration of polymer (2%), and were prepared with the same saline solution (0.3% w/w NaCl, acetate buffer 20mM at pH=5.5).

The rheology measurements were conducted with a Rheostress Haake RS150 controlled-stress rotational rheometer able to exert both sinusoidal and linear stresses on the sample; the sample deformation rate was measured at the same time. The rheometer was equipped with flat smooth or knurled plates. The measurements were thermostated at 25°C.

Flow curves that measure viscosity on variation of the stress applied were recorded on the three samples compared (Figure 2).

The viscosity of the three systems with low stress differs by several orders of magnitude, and the flow curves change dramatically from a profile typical of a viscous liquid (commercial HA) to that of an elastic solid (HA lipoate and crosslinked HA).

Figure 3 shows the mechanical spectra of the three different systems. In the typical behaviour of a solution, the viscous modulus (G") is greater than the elastic modulus (G') at low frequencies, while as the oscillation frequency increases, the two modules tend to cross. This behaviour is observed for the straight-chain ester lipoate solution (Example 1). In the typical profile of a gel, the modulus of elasticity prevails over the viscous modulus throughout the oscillation frequency range, and is practically constant. This trend is observed in the microgel dispersion prepared according to Example 5.
CLAIMS

1. Polysaccharides containing glucosamine or galactosamine residues in the repetitive unit, characterised by the presence of esters on the hydroxyls, or amides on the amine functions, with lipoic acid or with mixtures of lipoic acid and formic acid.

2. Acid polysaccharides as claimed in claim 1, wherein the polysaccharide is a glycosaminoglycan.

3. Acid polysaccharides as claimed in claim 2, wherein the glycosaminoglycan is selected from hyaluronic acid, chondroitin sulphate, dermatan sulphate, heparan sulphate and ceratan sulphate.

4. Acid polysaccharides as claimed in claims 1-3, wherein the carboxyl function is present in acid form or salified with alkaline metals, in particular sodium.

5. Polysaccharides as claimed in claim 1, wherein the polysaccharide is chitosan.

6. Polysaccharides as claimed in claim 1, wherein the molecular weight of the polysaccharide is between 10^3 and 10^7 daltons.

7. Polysaccharides as claimed in claim 1, wherein the polysaccharide is a derivative of hyaluronic acid with a molecular weight included between 10^4 and 10^6 daltons.

8. Polysaccharides as claimed in claim 2, characterised in that the degree of esterification of lipoic acid on the hydroxyls of the polymer is between 0.01 and 0.5 *N, where N is the number of free alcohol groups present in the repetitive unit, while the degree of esterification of formic acid on the hydroxyls of the polymer is between 0 and 0.20.

9. Polysaccharides as claimed in claim 5, characterised in that the degree of amidation of lipoic acid on the chitosan amine group is between 0.01 and 1.
while the degree of esterification of formic acid on the hydroxyls of the chitosan is between 0 and 0.20.

10. Polysaccharides as claimed in claim 8, wherein the acid polysaccharide is hyaluronic acid, and the degree of esterification of lipoic acid on the hydroxyls of the polymer is between 0.01 and 0.8, while the degree of esterification of formic acid on the hydroxyls of the polymer is between 0 and 0.20.

11. Polysaccharides as claimed in claim 1, wherein the acid polysaccharide is hyaluronic acid, and the degree of esterification of lipoic acid on the hydroxyls of the polymer is between 0.01 and 0.8, the degree of esterification of formic acid on the hydroxyls of the polymer is between 0 and 0.20, and the degree of crosslinking is between 0.001 and 0.1, as regards the ester groups between two different hyaluronic acid chains.

12. Preparation process for the polysaccharides claimed in claims 1 to 10, which comprises the following steps:

   a) dissolving in formamide chitosan in salified form, preferably hydrochloride, or acid polysaccharide salified with sodium or other alkaline metals, by heating;

   b) adding to the resulting solution lipoic acid pre-activated by carbonyldiimidazole in the presence of an organic base, at room temperature;

   c) reacting the reaction mixture at room temperature for between 1 and 24 hours;

   d) diluting the reaction mixture with a buffered aqueous solution and neutralising it to pH 6-7.5;

   e) purifying the dilute reaction mixture by precipitation with a suitable solvent, dialysis or tangential filtration;

   f) recovering the product by filtration or spray-drying, or freezing
the purified aqueous polysaccharide solution and recovering the
product by freeze-drying.

13. Process as claimed in claim 12, wherein the base is an aromatic or
aliphatic organic base comprising one atom of trisubstituted nitrogen,
preferably dimethylaminopyridine, 4-pyrrolidine-pyridine or triethylamine.

14. Process for the preparation of cross-linked hyaluronic acid as claimed in
claim 11, which comprises the following steps:

   a) dissolving hyaluronic acid salified with sodium or other alkaline
      metals in formamide by heating;
   b) adding to the resulting solution lipoic acid pre-activated by
      carbonyldiimidazole, at room temperature;
   c) reacting the reaction mixture at room temperature for between 4
      and 24 hours;
   d) diluting the reaction mixture with a buffered aqueous solution
      and neutralising to pH 6-7.5;
   e) purifying the dilute reaction mixture by dialysis;
   f) freezing the purified aqueous polysaccharide solution and
      recovering the product by freeze-drying.

15. Process as claimed in claims 12 and 14, wherein the temperature of
solubilisation of the polysaccharide in formamide is between 60°C and 120°C,
and preferably 95°C.

16. Process for the preparation of polysaccharides as claimed in claim 1,
wherein the presence of formate ester, if any, originates from hydrolysis of
formamide under the experimental conditions described in claims 12 and 14.

17. Topical compositions comprising the polysaccharide derivatives
claimed in claims 1-11, and inert, dermatologically acceptable excipients.

18. Topical compositions as claimed in claim 17, containing the
polysaccharide in percentages of between 0.05% and 5% by weight of the
composition.

19. Topical compositions as claimed in claim 17, in the form of creams, ointments, gels, hydrophilic liquids, aqueous or water-alcohol lotions, oil/water or water/oil emulsions.

20. Polysaccharides as claimed in claims 1-11 as topical moisturising, elasticising, toning, antioxidant, antiradical, anti-aging and anti-acne agents.

21. Polysaccharides as claimed in claims 1-11 for the treatment, as adjuvants, of skin lesions.

22. Polysaccharides as claimed in claims 1-11 for the treatment of skin lesions caused by inflammation, chronic ulcers, wounds, atopic or contact dermatitis, and radiation-induced skin hyperthermia.

23. Medical device in the form of a syringe containing a hydrogel of cross-linked hyaluronic acid lipoate prepared as claimed in claim 11, swollen in sterile saline solution at a polymer concentration of between 0.3% and 3% weight/volume.

24. Medical device as claimed in claim 23, as viscosupplementation agent for intra-articular application.

25. Medical device as claimed in claim 23, as skin filler for cosmetic surgery applications.

26. Medical device containing a hyaluronic acid derivative as claimed in claim 7 as eyedrops for the treatment of forms of conjunctivitis and keratitis of different etiologies.
Figure 1
Figure 2
Figure 3
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER

INV. C08B37/00 C08B37/08 A61K31/715 A61K31/722 A61K31/726
A61K31/728 A61K31/737 A61K31/728

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C08B A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal , CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Y</td>
<td>WO 2006/128618 A (FIDIA ADVANCED BIOPOLYMERS SRL [IT]; SORANZO CARLO [IT]; SENIGAGLIA DO) 7 December 2006 (2006-12-07) cited in the application page 5, line 12 - page 6, line 4</td>
<td>1-26</td>
</tr>
<tr>
<td>Y</td>
<td>WO 03/008457 A (EURAND PHARMACEUTICALS LTD [IE]; RASTRELLI ALESSANDRO [IT]; MIGLIERINI) 30 January 2003 (2003-01-30) page 7 - page 8; claims 10-13</td>
<td>1-26</td>
</tr>
</tbody>
</table>

X Further special categories of cited documents:

- "Y" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

Y later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

T document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

X member of the same patent family

Date of the actual completion of the international search: 8 April 2009

Date of mailing of the international search report: 17/04/2009

Name and mailing address of the ISA:

European Patent Office, P.B. 5818 Patentlaan 2
NL-2280 HV RIJSWIJK
Tel.: (+31-70) 340-2040
Fax: (+31-70) 340-3016

Authorized officer:

Gerber, Myri am

Form PCT/SA/210 (second sheet) (April 2006)
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Y</td>
<td>WO 00/01733 A (FIDIA ADVANCED BIOPOLYMERS SRL [IT]; BELLINI DAVIDE [IT]; TOPAI ALESSA) 13 January 2000 (2000-01-13) examples</td>
<td>1-19</td>
</tr>
<tr>
<td>Y</td>
<td>US 2 589 226 A (CARSON JOHN F) 18 March 1952 (1952-03-18) the whole document</td>
<td>1-16</td>
</tr>
<tr>
<td>Y</td>
<td>US 2004/265268 Al (JAIN DEEPAK [US]) 30 December 2004 (2004-12-30) claims 1,2,4</td>
<td>20-26</td>
</tr>
<tr>
<td>Patent document cited in search report</td>
<td>Publication date</td>
<td>Patent family member(s)</td>
</tr>
<tr>
<td>----------------------------------------</td>
<td>-----------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>WO 2006128618 A</td>
<td>07-12-2006</td>
<td>CA 2610305 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1890692 A1</td>
</tr>
<tr>
<td>WO 03008457 A</td>
<td>30-01-2003</td>
<td>CA 2453765 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1425308 A2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IT TS20010017 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2004536911 T</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NZ 530848 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2004171581 A1</td>
</tr>
<tr>
<td>WO 0001733 A</td>
<td>13-01-2000</td>
<td>AT 297413 T</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 761986 B2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 4639799 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2339066 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 69925733 D1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 69925733 T2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1095064 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ES 2244198 T3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IT PD980169 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 20.02519481 T</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2007031721 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PT 1095064 E</td>
</tr>
<tr>
<td>US 2589226 A</td>
<td>18-03-1952</td>
<td>NONE</td>
</tr>
<tr>
<td>us 2007207116 A</td>
<td>06-09-2007</td>
<td>NONE</td>
</tr>
<tr>
<td>us 2004265268 A</td>
<td>30-12-2004</td>
<td>NONE</td>
</tr>
</tbody>
</table>